Cytox have developed a simple genetic based blood test for the assessment of risk and diagnosis of Alzheimer&s;s Disease.
Business Model:
Revenue: $0
Employees: 1-10
Address:
City: Manchester
State: Manchester
Zip:
Country: United Kingdom
Cytox have developed a simple genetic based blood test for the assessment of risk and diagnosis of Alzheimer&s;s Disease in the very early stages. Alzheimer&s;s Disease affects over 26 million people world-wide and is a growing condition as people live longer. There is currently no cure for Alzheimer&s;s Disease, but there are large international initiatives underway to find treatments with many drugs in clinical development. Cytox are commercially launching their tests in conjunction with Affymetrix (part of Thermo Fisher Scientific) to support Pharmaceutical and Biotechnology companies developing novel therapeutics.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|